Clinical benefit, development, innovativeness, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations.

Daniel Tobias Michaeli Thomas Michaeli Sebastian Albers Julia Caroline Michaeli

Published in: Journal of the National Cancer Institute (2023)

Multiple special designations are associated with faster clinical development and greater benefits for patients with unmet needs; yet, also with non-robust trial evidence and a tendency for higher drug prices.

Keyphrases

clinical trial
papillary thyroid
study protocol
risk factors
young adults
electronic health record